Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × Epirubicin × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 125 Stomach Neoplasms 20 Triple Negative Breast Neoplasms 17 Inflammatory Breast Neoplasms 12 Carcinoma, Hepatocellular 12 Esophageal Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 6 Pancreatic Neoplasms 4 Neoplasms 4 Urinary Bladder Neoplasms 3 Testicular Neoplasms 3 Sarcoma 3 Primary Breast Cancer 3 Gallbladder Neoplasms 3 Carcinoma, Ductal, Breast 3 Adenocarcinoma Of Esophagus 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pathologic Complete Response 2 Non-Muscle Invasive Bladder Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Liver Neoplasms 2 Breast Neoplasms, Male 2 Breast Diseases 2 Women With Primary Breast Cancer 1 Wilms Tumor 1 Upper Tract Urothelial Carcinoma 1 Thymoma 1 Testicular Germ Cell Tumor 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡